Cannabis Use and CKD: Epidemiological Associations and Mendelian Randomization.
Cannabis Use and CKD: Epidemiological Associations and Mendelian Randomization.
复制标题
大麻使用和CKD：流行病学关联和孟德尔随机化。
DOI：
10.1016/j.xkme.2022.100582
复制
发表时间：
2023-02
影响因子：
3.7
通讯作者：
Nadkarni, Girish N.
中科院分区：
文献类型：
--
作者：
Dellepiane, Sergio;Paranjpe, Ishan;Rajagopal, Madhumitha;Kamat, Samir;O'Hagan, Ross;Gulamali, Faris;Rein, Joshua L.;Charney, Alexander W.;Do, Ron;Coca, Steven;Glicksberg, Benjamin S.;Nadkarni, Girish N.
大麻使用与慢性肾脏疾病（CKD）之间的关系是有争议的。我们的目的是在一项大型队列研究中评估CKD与大麻使用的关联，然后使用孟德尔随机化和全基因组关联研究（GWAS）来评估因果关系。回顾性队列研究和全基因组关联研究。回顾性研究在All of Us队列中进行(N=223,354)。大麻使用障碍的遗传工具从3个GWAS中确定：精神病学基因组学联盟物质使用障碍、iPSYCH和deCODE （N=384,032）。在CKDGen GWAS （nbbb120万）中研究了遗传仪器与CKD之间的关系。大麻消费。CKD结果包括：基于胱抑素c和肌酐的肾功能、蛋白尿和血尿素氮。我们进行了关联分析，以测试大麻使用频率和慢性肾病。为了评估因果关系，我们进行了双样本孟德尔随机化。在回顾性研究中，与前使用者相比，少于每月吸食大麻者（OR, 1.01; 95% CI, 0.87-1.18; P = 0.87）和每月吸食大麻者（OR, 1.15; 95% CI, 0.86-1.52; P = 0.33）没有更高的CKD几率。相反，每周（OR, 1.28; 95% CI, 1.01-1.60; P = 0.04）和每日使用（OR, 1.25; 95% CI, 1.04-1.50; P = 0.02）与CKD显著相关，经多个混杂因素校正。在孟德尔随机化中，大麻使用障碍的遗传倾向与CKD的几率增加无关（OR, 1.00; 95% CI, 0.99-1.01; P = 0.96）。这些结果在不同的孟德尔随机化技术和多种肾脏特征中都是稳健的。可能少报大麻使用情况。在孟德尔随机化中，遗传工具在GWAS中被确定，其中包括主要是欧洲血统的个体。尽管大麻使用与慢性肾病之间存在流行病学关联，但没有证据表明存在因果关系，这表明观察性研究存在混淆。
The association between cannabis use and chronic kidney disease (CKD) is controversial. We aimed to assess association of CKD with cannabis use in a large cohort study and then assess causality using Mendelian randomization with a genome-wide association study (GWAS). Retrospective cohort study and genome-wide association study. The retrospective study was conducted on the All of Us cohort (N=223,354). Genetic instruments for cannabis use disorder were identified from 3 GWAS: the Psychiatric Genomics Consortium Substance Use Disorders, iPSYCH, and deCODE (N=384,032). Association between genetic instruments and CKD was investigated in the CKDGen GWAS (N > 1.2 million). Cannabis consumption. CKD outcomes included: cystatin-C and creatinine-based kidney function, proteinuria, and blood urea nitrogen. We conducted association analyses to test for frequency of cannabis use and CKD. To evaluate causality, we performed a 2-sample Mendelian randomization. In the retrospective study, compared to former users, less than monthly (OR, 1.01; 95% CI, 0.87-1.18; P = 0.87) and monthly cannabis users (OR, 1.15; 95% CI, 0.86-1.52; P = 0.33) did not have higher CKD odds. Conversely, weekly (OR, 1.28; 95% CI, 1.01-1.60; P = 0.04) and daily use (OR, 1.25; 95% CI, 1.04-1.50; P = 0.02) was significantly associated with CKD, adjusted for multiple confounders. In Mendelian randomization, genetic liability to cannabis use disorder was not associated with increased odds for CKD (OR, 1.00; 95% CI, 0.99-1.01; P = 0.96). These results were robust across different Mendelian randomization techniques and multiple kidney traits. Likely underreporting of cannabis use. In Mendelian randomization, genetic instruments were identified in the GWAS that included individuals primarily of European ancestry. Despite the epidemiological association between cannabis use and CKD, there was no evidence of a causal effect, indicating confounding in observational studies.
登录
查看更多内容
DOI：
10.1056/nejmsr1809937
发表时间：
2019-08-15
期刊：
The New England journal of medicine
影响因子：
--
作者：
All of Us Research Program Investigators;Denny JC;Rutter JL;Goldstein DB;Philippakis A;Smoller JW;Jenkins G;Dishman E
通讯作者：
Dishman E
影响因子：
5.9
作者：
Lu, Chang;Papatheodorou, Stefania I.;Mittleman, Murray A.
通讯作者：
Mittleman, Murray A.
影响因子：
5.2
作者：
Bondy, S. J.;Victor, J. C.;Diemert, L. M.
通讯作者：
Diemert, L. M.
影响因子：
16.6
作者：
Stanzick KJ;Li Y;Schlosser P;Gorski M;Wuttke M;Thomas LF;Rasheed H;Rowan BX;Graham SE;Vanderweff BR;Patil SB;VA Million Veteran Program;Robinson-Cohen C;Gaziano JM;O'Donnell CJ;Willer CJ;Hallan S;Åsvold BO;Gessner A;Hung AM;Pattaro C;Köttgen A;Stark KJ;Heid IM;Winkler TW
通讯作者：
Winkler TW
影响因子：
7.7
作者：
Brion, Marie-Jo A.;Shakhbazov, Konstantin;Visscher, Peter M.
通讯作者：
Visscher, Peter M.